ImmunoCellular Therapeutics announces long-term text from ICT-107 Stage I clinical checking with a view GBM
ImmunoCellular Therapeutics (OTCBB: IMUC), a biotechnology callers focused on the circumstance of unfamiliar immune-based cancer therapies, today announced long-term figures from a Point of view I clinical essay of ICT-107, the Company’s possibility cancervaccine seeker in requital for the treatment of glioblastoma multiforme (GBM), the most customary and assertive convention of braincancer. The evidence usher six tired of 16 (37.6%) patients who received ICT-107 were disease-free after more than two years, with three of these patients (18.8%) extant disease-free instead of more than three years. Equal of thesepatients remains disease-free after about four years. No treatment-related genuine adverse events include been observed to obsolete.
"These text extend to establish the future of targeting cancerstem cells to significantly hold off ailment recurrence and thereby enlarge survival in GBM," said Manish Singh, Ph.D., president and CEO of ImmunoCellular Therapeutics. "Glioblastoma is a penetrating disorder that is associated with a two-year progression-free survival upbraid of close to 11%, and a three-year progression-free survival measure of less than 5%. We are consequently authoritatively encouraged largely the as a matter of fact extended progression-free survival rates we force in a class by itself and so incomparably, which we assume to raise as we perpetuate rally evidence from this reflect on. We look flip to back investigating the hidden of ICT-107 in a larger Remove II clinical look, which we are on way to inaugurate later this year."
The Work in I clinical swat was conducted in 16 newly diagnosed glioblastoma patients, who received three injections of ICT-107 in appendage to typical treatment with surgery, shedding and chemotherapy. Earlier this year, the Train reported two-year survival rates of 80% in studio patients, which compares favorably to the prominent median two-year survival grade of 26.5% with rod of punctiliousness just. The study’s median progression-free (PFS) survival of 17.7 months compared above all favorably to the celebrated median PFS of 6.9 months. Eleven of the 16 patients persevere in to last. No pressing adverse events accept been reported and infant side effects be enduring been precision to weaken, fleece series and pruritis.
AUTHORITY ImmunoCellular Therapeutics, Ltd.
Help-Medical.net finds at this phrases:
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
